Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03794544
Title Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedImmune LLC
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Oleclumab

AZD9150 + Durvalumab

Durvalumab

Durvalumab + Monalizumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN

Facility Status City State Zip Country Details
Research Site La Jolla California 92093 United States Details
Research Site Fort Myers Florida 33901 United States Details
Research Site Leesburg Florida 34748 United States Details
Research Site Baltimore Maryland 21231 United States Details
Research Site Buffalo New York 14263 United States Details
Research Site New York New York 10016 United States Details
Research Site Chattanooga Tennessee 37404 United States Details
Research Site Nashville Tennessee 37203 United States Details
Research Site Houston Texas 77030 United States Details
Research Site Fairfax Virginia 22031 United States Details
Research Site Montreal Quebec H4A 3J1 Canada Details
Research Site Marseille Cedex 9 13009 France Details
Research Site Toulouse CEDEX 09 31059 France Details
Research Site Orbassano 10043 Italy Details
Research Site Porto 4200-072 Portugal Details
Research Site A Coruña 15001 Spain Details
Research Site Barcelona 08916 Spain Details
Research Site Zurich 8091 Switzerland Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field